AlzeCure Pharma publishes its Annual Report for 2023

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that its Annual Report for 2023 has been published.

“2023 continued to be positive and eventful for AlzeCure Pharma. During the year, we presented positive proof-ofmechanism (POM) results from our Phase II clinical study with ACD440 for the treatment of neuropathic pain. Further, we chose a new candidate drug for our Alzheimer’s project, Alzstatin, and we also published new preclinical data for our clinical drug candidate NeuroRestore ACD856, which supports neuroprotective and disease-modifying effects. This advancement is highly relevant for treatment of Alzheimer’s and other neurodegenerative diseases. We were also granted patents for ACD856 in additional territories, such as in Europe and Japan, further strengthening our business development opportunities. Furthermore, we have now also selected a drug candidate in our TrkA-NAM project, ACD137. It is both motivating and gratifying that we are keeping up the pace as we continue to deliver new data that strengthen our position,” says Martin Jönsson, CEO of AlzeCure Pharma.

The Annual Report is available on the company’s website, https://www.alzecurepharma.se/en/section/investors/financial-reports/